Dermapharm Holding SE

XETRA DMP.DE

Dermapharm Holding SE Price to Earnings Ratio (P/E) on January 14, 2025: 32.24

Dermapharm Holding SE Price to Earnings Ratio (P/E) is 32.24 on January 14, 2025, a -8.81% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Dermapharm Holding SE 52-week high Price to Earnings Ratio (P/E) is 35.36 on January 15, 2024, which is 9.66% above the current Price to Earnings Ratio (P/E).
  • Dermapharm Holding SE 52-week low Price to Earnings Ratio (P/E) is 25.92 on October 30, 2024, which is -19.60% below the current Price to Earnings Ratio (P/E).
  • Dermapharm Holding SE average Price to Earnings Ratio (P/E) for the last 52 weeks is 30.43.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
XETRA: DMP.DE

Dermapharm Holding SE

CEO Dr. Hans-Georg Feldmeier
IPO Date April 12, 2018
Location Germany
Headquarters Lil-Dagover-Ring 7
Employees 3,603
Sector Health Care
Industries
Description

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

StockViz Staff

January 15, 2025

Any question? Send us an email